USFDA completes inspection at Granules India’s Gagillapur, Jeedimetla facilities

26 Mar 2018 Evaluate

Granules India's Gagillapur and Jeedimetla facilities located at Hyderabad, Telangana, has completed the US Food and Drug Administration (USFDA) inspection from March 19, 2018 to  March 23, 2018 without any 483 observations for Gagillapur facility and with one 483 observation for Jeedimetla facility. The company will respond to this observation within the stipulated time period.

Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs) whereas Jeedimetla facility manufactures Active pharmaceutical ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.